InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,099.96
(
1.02%
)
US TECH 100
17,244.00
(
1.57%
)
Dow Jones
38,239.66
(
0.40%
)
Brent Oil
88.17
(
0.00%
)
Bitcoin
63,842.65
(
0.16%
)
Post# of 146
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

whytestocks

Send PM Follow Ignore
Followers 130
Posts 14996
Boards Moderated 1
Alias Born 06/04/2018

whytestocks

Re: None

Friday, 07/05/2019 9:00:26 AM

Friday, July 05, 2019 9:00:26 AM

Post# of 146
News: $CYAD Celyad Presents Update on Autologous & Allogeneic NKG2D-based CAR-T Therapies in Solid Tumors

Preliminary interim results from the alloSHRINK Phase 1 trial demonstrate no evidence of GvHD for first-in-class, non-gene edited allogeneic NKG2D-based CAR-T candidate CYAD-101 when administered concurrently with FOLFOX chemotherapy for the treatment of metastatic colorectal cancer (mCRC...

Read the whole news Celyad Presents Update on Autologous & Allogeneic NKG2D-based CAR-T Therapies in Solid Tumors
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up